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Abstract ( < 150 words) 
Members of matrix metalloproteinase (MMP) family promote cancer cell migration, invasion, 
and metastasis through alteration of the tumor milieu, intracellular signaling pathways, 
transcription. We examined gene expression signatures of colon adenocarcinoma cell lines with 
different metastatic potentials and found that rapidly metastatic cells powerfully expressed 
genes encoding MMP3 and MMP9. The non-proteolytic PEX isoform and proteolytic isoforms 
of MMPs were significantly expressed in the metastatic cells in vitro. Knockdown of MMP3 
attenuated cancer cell migration and invasion in vitro and lung metastasis in vivo. Profound 
nuclear localization of MMP3 / PEX was found in tumor-stroma marginal area. In contrast, 
MMP9 was localized in central area of subcutaneous tumors. Overexpression of the PEX 
isoform of MMP3 promoted proliferation and migration of the rapidly metastatic cells in vitro. 
Taken together, the non-proteolytic PEX isoform of MMPs locating in cell nuclei involves 
proliferation, migration, and subsequent metastasis of aggressive adenocarcinoma cells. 
 
 
 
Page 3 of 79
John Wiley & Sons, Inc.
Journal of Cellular Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
INTRODUCTION 
Metastasis is a critical phenomenon in cancer. Over time, malignant cancer cells undergo clonal 
evolution, which promotes their diversity and heterogeneity, as well as therapy resistance 
[Greaves and Maley, 2012; Kreso and Dick, 2014; Nowell, 1976]. In addition, it has been 
proposed that highly evolved clones of cancer cells are resistant to selective pressure by the 
immune, chemo- and radiation therapies. Although previously considered to be mutually 
exclusive models, it is recently considered that genetic evolution and cancer stem cell models 
can be harmonized in three related biological fields; tumor genetics, epigenetics and pathways, 
and microenvironment [Kreso and Dick, 2014]. Matrix metalloproteinases (MMPs) represent 
the most prominent family of proteinases associated with tumorigenesis and regulators of the 
tumor microenvironment [Kessenbrock et al., 2013; Kessenbrock et al., 2010]. MMPs have also 
been reported to be potent biomarkers of tumor progression as well as one of the causal factors 
that promote multiple processes of tumorigenesis, including oxidative stress-dependent DNA 
damage and chromosomal instability, epithelial-to-mesenchymal transition (EMT) [Radisky et 
al., 2005], migration and invasion of cancer cells [Sato H et al., 1994], angiogenesis, and 
metastasis [Kessenbrock et al., 2013; Kessenbrock et al., 2010; Vandenbroucke and Libert, 
2014].  Canonical proteolytic roles for MMPs is to cleave substrate proteins at extracellular 
space. Proteolysis of extracellular matrix (ECM) and intercellular adhesion molecules by MMPs 
enable cells to migrate and invade and to release cytokines, chemokines, and growth factors that 
activate their receptors and intracellular signaling pathways. In addition to those indirect 
activations of the extracellular factors, MMPs also directly alter activities of growth factors, 
cytokines, and chemokines by proteolysis. For example, MMPs are able to cleave connective 
tissue growth factor (CTGF/CCN2) and then release VEGF leading to angiogenesis [Hashimoto 
et al., 2002]. Another study showed that MMPs and a disintegrin and metalloproteinases cleave 
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membrane-bound heparin-binding EGF-like growth factor (HB-EGF) and release soluble 
HB-EGF, which binds to cells and stimulates EGFR/ERBB signaling [Prenzel et al., 1999].  
Intracellular and nuclear roles for MMPs have been recently discovered. We showed 
that MMP3 possesses nuclear localization signals and can translocate into cellular nuclei, in 
which MMP3 can bind to chromatin proteins and DNA leading to transcriptional regulation of 
CTGF/CCN2 gene [Eguchi et al., 2008]. MMP3 is composed of a protease domain, a hinge 
region, and a C-terminal hemopexin-like repeat (PEX) domain, which is non-proteolytic (see 
later figure). We recently showed that a PEX isoform of MMP3 activate some members of heat 
shock protein (HSP) genes [Eguchi et al., 2017], which can contribute to anti-apoptosis and 
drug resistance. MMP3 can interact with heterochromatin proteins, members of the chromobox 
protein family that involve transcriptional and chromosomal control [Eguchi et al., 2017; 
Eguchi et al., 2008; Eguchi et al., 2010]. MMPs also involve oxidative stress, DNA damage, and 
chromosome instability in cell nuclei. Intranuclear MMP2 and MMP9 activities have been 
shown to cleave PARP-1 and XRCC1, nuclear matrix proteins, thus promoting oxidative DNA 
damage and apoptosis in an ischemic injury model [Yang et al., 2010]. MMP3-induced EMT 
and genomic instability have been shown to be mediated by small GTPase Rac1b and a reactive 
oxygen species in breast adenocarcinoma and pancreatic cancer [Mehner et al., 2014; Radisky et 
al., 2005], indicating potent roles for MMPs in proteotoxic and genotoxic stress.  
MMPs appear to be appropriate target molecules in treatments of aggressive types 
of cancers. Although more than 50 MMP inhibitors have been investigated in clinical trials for 
various cancers, all of those trials failed [Vandenbroucke and Libert, 2014]. However, the 
involvement of intracellular and non-proteolytic roles for MMPs in cancer have not 
well-investigated yet.  
In the present study, we first investigated gene expression of MMPs correlated with 
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metastatic phenotype of colon cancer cells. We then assessed nuclear localization of the PEX 
domain of MMP3 and MMP9 in primary and lung-metastatic tumors and their roles in 
proliferation, migration, invasion and metastasis of the aggressive cancer cells. 
 
MATERIALS AND METHODS 
Cells. Colon26 (also known as colon26), LuM1, and NM11 cells were maintained in RPMI1640 
with 10% FBS supplemented with penicillin, streptomycin, and amphotericin B [Hyuga S et al., 
1994; Sakata K et al., 1996; Tsuruo et al., 1983].  
 
Comprehensive gene expression analysis and bioinformatics. Cells were cultured for 3 days 
and total RNA was extracted from cultured cells using the AGPC method with Trizol 
(Molecular Research Center, Cincinnati, OH). Concentration and quality (A260/A280) of total 
RNA were determined. cDNA was synthesized from 0.1 µg of total RNA using a Low Input 
Quick Amp Labeling Kit (Agilent Technologies, Santa Clara, CA), then hybridized to probes of 
a SurePrint G3 Mouse GE 8x60 K v.2 Microarray system (Agilent Technologies, Santa Clara, 
CA). Gene expression and ratios were analyzed using MeV 4.0 software 
(http://www.Tm4.org/mev.html). Functional annotation clustering and pathway analysis were 
performed with LuM1 genes expressed at a 10-fold or higher level as compared to the NM11 
and Colon26 cells (p < 0.05) using DAVID Bioinformatics Resources 6.8. Relative expression 
levels in LuM1 or NM11 to the levels in Colon26 were shown in heat maps and bar graphs. 
 
RNAi. Cells were transfected with small interfering RNA (siRNA) targeting mRNA of Mmp3 or 
Mmp9 (ON-TARGETplus SMARTpool siRNA; Thermo Fisher Scientific, Rockford, IL), or 
non-targeting double strand RNA (dsRNA) (siGENOME Control Pool Non-Targeting siRNA) at 
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a final concentration of 50 nM using DharmaFECT 1 (Thermo Fisher Scientific, Rockford, IL). 
Cells were cultured for 48 hours before RT-qPCR, Western blot, migration assay, invasion assay 
and subcutaneous injection and for 72 hours before zymography. For analysis of culture 
supernatant, cells were cultured for 48 hours in serum-containing medium and subsequently 24 
hours in serum-free medium. To examine mRNA levels in tumors, total RNA was extracted 
from subcutaneous tumors on the day 10 after subcutaneous injection. Lung metastasis assay 
and immunohistochemistry (IHC) were performed on the day 20 after subcutaneous injection as 
depicted in Fig. S2A. 
 
Real-time RT-qPCR. Total RNA preparation and RT-qPCR was carried out as described 
previously [Eguchi et al., 2017; Eguchi et al., 2008]. The miRNeasy mini kit (Qiagen) was used 
with DNase (Qiagen). Total RNA concent ation was measured by using a microspectrometer 
K2800 (Beijing Kaiao, Beijing, China). cDNA synthesis was carried out by using iScript™ 
cDNA Synthesis Kit (Bio-Rad). Specific primer pairs for Mmp3, Mmp9, Actb, and Gapdh were 
used as follows: mMMP3Fw, 5’-ACC AAC CTA TTC CTG GTT GCT GCT and mMMP3Rv, 
5’-ATG GAA ACG GGA CAA GTC TGT GGA [Ma et al., 2009]; mMMP9Fw, 5’-CAG CCG 
ACT TTT GTG GTC TT and mMMP9Rv, 5’-GCT TCT CTC CCA TCA TCT GG [Sousa et al., 
2014]; mGapdhFw, 5’-ACC ACA GTC CAT GCC ATC AC and mGapdhRv, 5’-TCC ACC ACC 
CTG TTG CTG TA [You et al., 2012]; mActb-Fw, 5’-AAC GAG CGG TTC CGA TG and 
mActb-Rv, 5’-GGA TTC CAT ACC CAA GAA GGA [Sousa et al., 2014]. Realtime PCR was 
carried out using iQ SYBR Green PCR mixture (Bio-Rad). Relative mRNA levels to Actb or 
Gapdh mRNA levels were quantified by the ΔΔCt method using the formula as follows: fold 
change = 2
-ΔΔCt. PCR was carried out in triplicate and mean values were calculated with the 
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mean ± S.D. of biological triplicates. 
 
Migration and invasion assays. Migration and invasion assays were performed as previously 
described [Sakata K et al., 1996]. Uncoated and Matrigel-coated culture systems (Becton 
Dickinson) were used for in vitro migration and invasion assays, respectively. For knockdown 
experiments, cells were transfected with siRNA and then cultured for 48 hours before re-seeding 
to upper chambers. Cells were seeded at concentrations of 5 × 10
4 
per an upper chamber of a 
Transwell® 24-well (Corning) for the migration assay and of 2.5 × 104 per an upper chamber of 
a Transwell® 24-well for the invasion assay. Cells transfected with PEX-overexpressing or 
control plasmids were seeded at concentrations of 5 × 104 per an upper chamber of a Transwell® 
24-well for the migration assay and of 1.6 × 10
4 
per an upper chamber of a Transwell® 24-well 
for invasion assay. Cells that migrated or invaded through the pores to the lower surface of filter 
were fixed, stained using Diff-Quick stain (Sysmex) and counted after 6 hours of migration 
period or 19 hours of invasion period for knockdown experiments, and after 0, 12 and 24 hours 
for comparison of different cell lines. To evaluate the effects of the transfection, percentages of 
migrated and invaded cells relative to the control were calculated. 
 
Cell proliferation. Cells were transfected with siRNA or plasmid DNA and then seeded at a 
concentration of 3.8 x 10
3 
cells / well in a 96-well plate on the day 2 after transfection. Number 
of cells at 1 to 4 days post-transfection period were counted by using Countess automated cell 
counter (Invitrogen). Floid® cell imaging station (ThermoFisher Scientific) was used for 
photomicrography. 
 
Allogeneic transplantation. All animal experiments were performed according to the 
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guidelines for care and use of laboratory animals approved by Okayama University and the 
Japanese Pharmacological Society. Subcutaneous allogeneic transplantation was performed as 
previously described [Sakata K et al., 1996], with 5.0 x 105 cells transplanted subcutaneously 
into a side abdominal wall of each 6 to 7-week-old BALB/c mouse. Twenty days after 
transplantation, subcutaneous tumors and lungs were resected, then fixed with Bouin’s fluid. 
Nodules larger than 0.5-mm-diameter were counted. 
 
Casein and gelatin zymography. For zymography of non-transfected cells, cells were 
inoculated at a concentration of 2 x 10
6
 cells into 60-mm culture dishes in 4 ml of RPMI1640 
containing 10% FBS and cultured overnight, then incubated in serum-free medium for 24 hours. 
Cell culture supernatants were concentrated 20 times using an Amicon filtration tube (for MW 
10,000). Cells were washed with PBS, collected using a cell scraper, and lysed in RIPA buffer 
containing a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO), then further lysed by 
homogenization (25-gauge needle, 10 strokes) and incubated for 30 minutes on ice. Lysates 
were centrifuged at 12,000 x g for 20 minutes to remove debris and supernatants were used as 
cell lysates. Twenty microgram of cell lysates or 4 µg of cell culture supernatants were mixed 
with an SDS sample buffer and CaCl2 (5 mM final concentration), then applied to 10% 
acrylamide gel containing copolymerized 0.1% gelatin (Cosmo Bio, Tokyo, Japan). For 
zymography with knockdown experiments, cells were cultured in 6-well plates. At 48 hours 
after transfection, medium was replaced with serum-free medium and cells were cultured for 24 
hours, then the supernatants were ultra-filtrated and concentrated as described above. Following 
a protein assay, 9 µg of the >10-kDa cell culture supernatant was mixed with a 2x sample buffer  
(10 µl) and 1 µl of 50 mM CaCl2, then separated on 10% acrylamide gels containing 
copolymerized 0.1% gelatin or 0.5% casein (CosmoBio, Tokyo, Japan). The gels were washed 
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with wash buffer for 30 minutes at RT and incubated for 40 hours in enzyme reaction buffer at 
37˚C. Coomassie Brilliant Blue staining was performed and photographs of the gels were 
obtained, then quantitative densitometric analysis was performed using Image J. 
 
Western blotting analysis. Cells were seeded into 6-well plates and transfected with siRNA 
using the procedure described above, then lysed in RIPA buffer as described above. Next, 30-µg 
protein samples were separated by SDS-PAGE on 10% poly-acrylamide gels and transferred to 
PVDF membranes. The membranes were blocked in Tris-buffered saline containing 0.05% 
Tween 20, 2.5% skim milk, and 2.5% BSA for 30 minutes at room temperature (RT). Each 
membrane was incubated with the primary antibody (1/1000) overnight at 4˚C and subsequently 
incubated with horseradish peroxidase (HRP)-conjugate secondary antibodies against anti-rabbit 
IgG (GE Healthcare) (1/2000) for 1 hour at RT in the blocking solution. Blots were visualized 
with a Clarity Western ECL Substrate (Bio-Rad). 
 
Antibodies. Rabbit monoclonal anti-PEX domain MMP3 antibody (EP1186Y, ab52915) and a 
rabbit polyclonal anti-MMP9 antibody (ab38898, full-length protein corresponding to mouse 
MMP9 was immunized) were purchased from Abcam. 
 
Immunohistochemistry. Excised tumor tissues were immediately fixed in Bouin’s fluid, then 
dehydrated by passage through an ethanol series and embedded in paraffin. Samples were cut 
into 4-µm serial sections, which were then placed onto saline-coated slides. Deparaffinized 
sections were treated with methanol containing 0.3% H2O2 for 30 minutes to block endogenous 
peroxidase activity. Sections were then autoclave heated in 10 mM of citrate buffer solution (pH 
6.0) for 10 minutes at 120˚C for antigen retrieval. Blocking was performed using a Dako Chem 
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Mate Envision Kit/HRP. Sections were incubated with the anti-MMP3 antibody (ab52915; 
1/100) overnight at 4˚C and subsequently with a secondary antibody against anti-rabbit IgG 
HRP-conjugated (K400211-2, EnVision+ Single Reagents, Dako) for 1 hour at 4˚C. IHC 
reaction products were visualized by use of a diaminobenzidine chromogen substrate. Samples 
were then counterstained with hematoxylin and observed with a BZ-X700 (Keyence, Osaka, 
Japan). For a negative control, sections were incubated with omission of the primary antibody 
under the same protocol. 
 
Immunofluorescence and confocal microscopy. For immunofluorescence staining, excised 
tumor tissues were immediately fixed in Bouin’s fluid, then dehydrated by passage through an 
ethanol series and embedded in paraffin. Samples were cut into 4-µm serial sections, which 
were then placed onto saline-coated slides. Blocking was performed using a Dako Chem Mate 
Envision Kit. Sections were incubated with the anti-MMP3 antibody (ab52915; 1/100) and the 
anti-MMP9 antibody (ab38838; 1/500) overnight at 4˚C and subsequently with a secondary 
antibody against anti-rabbit IgG (ab150076; 1/5000) for 1 hour at 4˚C. For a negative control, 
sections were incubated with omission of the primary antibody under the same protocol. After 
three washes with TBS, the mounting and DNA staining were performed by using ProLong gold 
AntiFade reagents with 4_,6-diamino-2-phenylindole (DAPI) (Molecular Probes, Invitrogen). 
Fluorescence images were taken using a confocal laser scanning microscopy LSM780 (Carl 
Zeiss). We defined four areas of a subcutaneous tumor as follows: the stromal as an outside of 
the tumor margin, the marginal as an area 0 to 30 µm apart from the tumor margin, the interior 
as an area 30 to 80 µm apart from the outside of the marginal area. According to this definition, 
MMP3/9 and/or DAPI positive cells in each area were counted using Image J. The nuclear 
MMP positive rate was calculated as follows: MMP3/9 and DAPI double positive nuclei per 
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DAPI positive nuclei. 
 
Plasmid constructs and transfection. pFlag3-PEX-myc and pFlag3-myc were described 
previously [Eguchi et al., 2018]. These plasmid constructs were transfected using NEPA21 
electroporator (NEPA Gene, Ichikawa, Japan). To optimize transfection condition and efficiency 
for LuM1, ten different conditions of electroporation was tested. An optimized electroporation 
condition with 150V and 5 ms pulse twice was then used for plasmid transfection. 
 
Statistical analysis. Statistical significance was calculated using Microsoft Excel. Three or 
more mean values were compared using one way analysis of variance (ANOVA), while 
comparisons of 2 were done with an unpaired Student's t-test. p < 0.05 was considered to 
indicate statistical significance. 
 
RESULTS 
Gene expression signatures and gene screening of high- and low-metastatic cancer cell 
lines. 
We first examined gene expression signatures of colon adenocarcinoma cell lines with different 
metastatic potentials in high-metastatic LuM1, low-metastatic NM11 and the parental Colon26 
cells. To characterize these cell types with different invasive and metastatic potentials at gene 
expression levels, microarray analysis was carried out. (Raw data was submitted to the Gene 
Expression Omnibus (GEO) database repository; accession ID: GSE97166; Colon26, 
GSM2553008; LuM1, GSM2553009; NM11, GSM2553010.) Among the 62,976 genes tested, 
479 genes were strongly expressed at a greater than 10-fold higher level in the metastatic LuM1 
as compared to the low-metastatic lines (Fig. 1A; Fig. S1). Functional annotation clustering and 
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pathway analysis then revealed that the gene expression signature of LuM1 involved particular 
biological events in the extracellular microenvironment, cell adhesion, immunology, and protein 
interactions (Table 1, 2). In addition, functional classification of those LuM1-specific genes 
indicated that these 104 genes specifically expressed in LuM1 involved cancer cell invasion, 
EMT, and metastasis (Fig. 1B). These results indicated that more than a hundred 
metastasis-related genes involved metastatic, invasive and transforming potential of the LuM1 
cells. Among the 104 metastasis-related genes expressed specifically in LuM1 cells, several 
members of Mmp gene family, were profoundly expressed. We therefore examined Mmp 
expression signatures in the LuM1, NM11, and Colon26 cells. Of note, the gene expression 
level of Mmp3 in the metastatic LuM1 was the highest among all Mmp gene family members 
and higher than that in Colon26 and NM11 (2400.9-fold and 4.6-fold, respectively, Fig. 1C, D; 
Fig. S1C) . Mmp9 was also expressed in the LuM1 at a high level, as compared to the 
low-metastatic Colon26 and NM11 (512.1-fold and 237.8-fold, respectively, Fig.1D). 
These results indicate that Mmp3 and Mmp9 were profoundly co-expressed in the 
metastatic adenocarcinoma cells. 
 
Targeted knockdown of MMP3 attenuates proliferation, migration and invasion of the 
metastatic adenocarcinoma cells. 
We next examined migration and invasion activities of metastatic LuM1 cells and 
low-metastatic NM11 cells, as well as of their parental low-metastatic adenocarcinoma cell line 
Colon26. LuM1 showed the highest levels of migration and invasion as compared to the other 
low metastatic lines (Fig. 2A-C). We then examined siRNA-mediated knockdown of MMP3 and 
MMP9. Both MMP3 and MMP9 at mRNA levels were specifically and efficiently reduced by 
their targeted siRNA (Fig. 2 D, E). (Later figures show knockdown at protein levels). Yet the 
Page 13 of 79
John Wiley & Sons, Inc.
Journal of Cellular Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
MMP3 siRNA increased the MMP9 mRNA level (Fig. 2E) and, in contrast, the MMP9 siRNA 
increased the MMP3 mRNA level (Fig. 2D), suggesting compensatory expression system of 
these essential MMPs. (Some mutual compensation was also seen in Western blotting and 
zymography as shown in later figures).  
 We next examined roles of MMP3 and MMP9 in regard to proliferation of LuM1 cells. 
The MMP3 siRNA (50 nM) tended to attenuate proliferation of the LuM1 cells whereas the 
MMP9 siRNA (50 nM) and MMP9/MMP3 siRNA mixture (each 25nM) did not (Fig. 2F, Fig. 
S2B). The MMP3 siRNA and MMP3/MMP9 siRNA attenuated the migration of LuM1 cells to 
46.9% and 51.3%, respectively, of the level of the control (Fig. 2G), and attenuated invasion to 
71.0% and 59.7%, respectively (Fig. 2H). The MMP9 siRNA attenuated migration of the LuM1 
to 69.6%, which was a lesser effect as compared to MMP3-targeting, and did not alter invasion 
(Fig. 2G, H).  
 These results indicate that MMP3 is a key protein in the proliferation, migration, and 
invasion of the aggressive adenocarcinoma cells. 
 
Targeted reduction of MMP3 and MMP9 attenuates primary and lung-metastatic 
tumorigenesis of the aggressive adenocarcinoma cells. 
We next examined whether knockdown of MMP3 and MMP9 could alter primary tumor 
development and lung metastasis of the LuM1 cells in the allogeneic transplantation 
experiments. As pilot studies, we tested sustainability of siRNA-mediated knockdown as 
follows. The RNAi effect on MMP9 was sustained for 96 hours after transfection to LuM1 cells, 
as shown by gelatin zymography (Fig. S2C). Of note, RNAi effects on Mmp3 and Mmp9 at 
mRNA levels were sustained in tumors in vivo even at day 10 after subcutaneous injection (Fig. 
S2D). Using this knockdown system, we examined whether MMP3- and MMP9-targeting 
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siRNA alter tumor development and metastasis. The weights of primary tumors were reduced by 
the MMP3 siRNA and the MMP9 siRNA on day 20 after the transplantation, as compared to the 
control (Fig. 3A, B). 
The number of metastatic nodules in lungs were significantly reduced by the MMP3 
siRNA, the MMP9 siRNA and the MMP3/MMP9 siRNA, as compared to the control (Fig. 3C, 
D). The weights of lungs bearing the metastatic nodules were significantly reduced by the 
MMP3 siRNA, the MMP9 siRNA and the MMP3/MMP9 siRNA, as compared to the control 
(Fig. 3E).  
These results suggest that targeted knockdown of MMP3 and MMP9 reduce primary 
tumor development and subsequent metastasis of aggressive adenocarcinoma cells. 
 
The intracellular non-proteolytic PEX domain of MMP3 and the short MMP9 were 
expressed in the metastatic adenocarcinoma cells.  
We next examined expression and proteolytic activities of several isoforms of the MMPs 
produced from the metastatic LuM1 cells, and examined siRNA-mediated knockdown of these 
in vitro, based on that MMPs had been historically demonstrated as extracellular proteases, 
whereas non-proteolytic and intracellular roles for MMPs have been recently shown [Eguchi et 
al., 2017; Eguchi et al., 2008]. Therefore, prior to detection, we organized structures of MMP3 
and MMP9 (Fig. 4A, B). We examined isoforms of MMP3 produced in the LuM1 cells at by 
performing siRNA-mediated knockdown and subsequent Western blotting analysis and 
zymography. (Full images of Western blot and zymography were shown in supplemental Fig. 
S3.) The anti-PEX domain MMP3 antibody detected both full-length 54-kDa (arrow) and short 
25-kDa PEX domain (arrowhead) of MMP3 (Fig. 4C). The MMP9 siRNA increased the PEX of 
MMP3 and decreased full-length MMP3 (Fig. 4C, compare lane 1 and lane 3), indicating 
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crosstalk between MMP3 and MMP9. We next examined MMP3 proteolytic activity in the 
culture supernatant of the LuM1 cells in casein zymography. The 54-kDa and 100-kDa 
proteinases lysed casein, and these were thought to be proteolytic MMP3 monomer and dimer, 
respectively (Fig. 4 D, control si). The proteolytic MMP3 monomer was reduced by the MMP3 
siRNA (arrow), whereas the proteolytic putative MMP3 dimer was not reduced by the MMP3 
siRNA, but reduced by MMP3/MMP9 siRNA (arrowhead) (Fig. 4D), indicating crosstalk 
between MMP3 and MMP9. As expected, the non-proteolytic 25-kDa PEX domain was not 
detected in the casein zymography. 
We next examined isoforms of MMP9 produced from the LuM1 cells. Intracellular 
gelatinase activities of approx. 90-kDa and 250-kDa proteinases were significantly found in 
both lysate (Fig. 4E) and culture supernatant (Fig. 4F) of the metastatic LuM1 cells, but at much 
lower levels in the other low-metastatic cell lines. The 90-kDa gelatinase was thought to be 
MMP9 and the 250-kDa gelatinase was thought to be oligomers of MMP9. 
We next examined knockdown of the intracellular and extracellular MMP9 produced 
by LuM1 cells. The anti-MMP9 antibody detected full-length (approx. 90-kDa, arrow), 
processed forms (64- and 67-kDa, arrowhead), and putative oligomer (250-kDa, asterisk) of 
MMP9 in the lysate of LuM1 cells (Fig. 4G). Gelatinase activities of the 90-kDa MMP9 in the 
cell culture supernatant of LuM1 cells treated with the MMP9 siRNA was lower than that 
treated with the control siRNA or the MMP3 siRNA (Fig. 4H). 
These results indicate that the non-proteolytic PEX domain of MMP3 and the short 
MMP9 were intracellularly produced in the metastatic adenocarcinoma cells. The siRNAs 
targeting MMP3/9 successfully reduced proteolytic and non-proteolytic intracellular and 
extracellular isoforms of MMPs.  
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Expression and nuclear localization of MMP3 in primary tumors and in metastatic lungs 
in allogeneic transplants. 
MMP3 was initially found as the first member of stromelysin, which lyse ECMs in stroma. 
Later studies have shown intranuclear localization and roles of MMP3 [Eguchi et al., 2017; 
Eguchi et al., 2008]. In the present study, Mmp3 was notably expressed in the metastatic LuM1 
in vitro. We next examined expression and subtumoral and subcellular localization of MMP3 in 
primary tumors and in lungs with metastatic tumors in an allogeneic transplant model. As it 
have been shown that the PEX domain of MMP3 has an essential role in transcriptional 
regulation [Eguchi et al., 2017], we used an anti-PEX MMP3 antibody in 
immunohistochemistry. MMP3 was expressed at relatively high levels at marginal zone of 
tumor parenchyma (P) to stroma (S) in primary tumors, but at lower levels in central area of the 
parenchyma (Fig. 5A, B). Notably, intranuclear MMP3 was found in both marginal 
parenchymal cells (arrowheads) and stromal cancer-associated fibroblast (CAF)-like cells 
(arrow) (Fig. 5C). 
We next examined subtumoral and subcellular localization of MMP3 in the metastatic 
lungs in the same model. MMP3-positive cells were found throughout the metastatic tumor 
nodules and in pulmonary alveolar locations (Fig. 5E). MMP3 was found inside nuclei (arrow) 
and the nuclear margins (arrowhead) of cells with nuclear polyploidy in metastatic tumors in the 
lung (Fig. 5F). 
These results indicate that extra- and intracellular MMP3 involve CAF-related 
invasion, nuclear polyploidy, and metastasis of the aggressive adenocarcinoma cells. 
 
Nuclear PEX domain / MMP3 localized in tumor-stroma marginal area and MMP9 
localized in central area of tumors. 
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To more precisely investigate the nuclear localization of MMP3/9 in tumors, we next used 
immunofluorescence and confocal laser scanning microscopy and examined nuclear MMP3/9 
positive rate in each tumor area. We defined four areas of a tumor as follows: central (Fig. 6A, 
left), interior, marginal and stromal areas (Fig. 6A, right). The rate of cells with nuclear MMP3 
was most significant in the stromal area (17.6 %) and next in the tumor marginal area (9.4 %) as 
compared to those in the interior (0.80 %) and central areas (0.73%) with the lower rate (Fig. 6B 
- D). On the other hand, nuclear MMP9 positive cells were found notably in the central area 
(2.5 %) as compared to the other areas (Fig. 6B, D). 
  We next assessed localization of MMP3 and MMP9 in a lung lesion with metastatic 
tumors. Tumor cells with nuclear MMP3/9 appeared to scatter throughout the metastatic cancer 
nodule in the lung and in pulmonary alveolar locations (Fig. 6E), consisting with IHC data 
shown in Fig. 5.  
Of note, DNA stained with DAPI appeared to be dot-like condensation in cell 
nuclei in both primary and metastatic tumors (Fig. 6C-E), indicating chromosomal condensation 
involving gene regulation. MMP3 and MMP9 appeared to co-localize with DNA (Fig. 6C-E, 
arrows), suggesting DNA-binding and gene regulation. MMP3 and MMP9 appeared to localize 
out of nuclei- cytoplasm or extracellular region as well. 
    These results indicate that nuclear PEX domain / MMP3 localized in primary 
tumor-stroma marginal area and lung-metastatic tumor nodules. Nuclear MMP9 localized in 
central area of primary tumors and in lung-metastatic tumor nodules. 
 
Overexpression of the PEX-domain promotes proliferation and migration of the metastatic 
cancer cells. 
We next asked whether the non-proteolytic PEX domain could alter proliferation, migration, 
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and invasion of the aggressively metastatic cancer cells. Overexpression of the PEX of MMP3 
significantly increased proliferation of LuM1 cells (Fig. 7A). Of note, overexpression of the 
PEX increased migration of LuM1 cells to 204% level of the control (Fig. 7B). Overexpression 
of the PEX tended to increase invasion of LuM1 cells to 127.1% level of the control (Fig. 7C), 
suggesting that protease activities of MMPs might promote invasion rather than the 
non-proteolytic PEX.  
These results indicate that the PEX-domain has key roles in abilities of proliferation 
and migration of the metastatic adenocarcinoma cells. 
 
DISCUSSION 
MMP family members are consist of secretory types (collagenases, gelatinases, stromelysins) 
and membrane types (MT-MMPs) and have crucial roles in the progression of diseases, 
including cancer, arthritis, and periodontitis. Most metalloproteinase inhibitors had been 
designed and, indeed, to block catalytic pockets that possess a zinc ion and proteinase activity. 
However, any metalloproteinase inhibitor has been approved for clinical application. Recent 
studies, including the present study, have shown intracellular and non-proteolytic roles for 
MMPs in arthritis and cancer [Eguchi et al., 2017; Eguchi et al., 2008; Eguchi et al., 2010]. In 
addition to in an arthritis model and in a chondrosarcoma-derived cell line [Eguchi et al., 2008], 
nuclear MMP3 was significantly found in primary tumors and in metastatic sites in allogeneic 
transplant model of the aggressive adenocarcinoma cells (Fig. 5, 6). Both the PEX isoform and 
full-length MMP3 were significantly found in the metastatic LuM1 cells (Fig. 4). The siRNA 
targeting MMP3 reduced both 25-kDa PEX isoform and 54-kD full-length MMP3 (Fig. 4C) and 
simultaneously attenuated proliferation and migration of the aggressive adenocarcinoma cells 
(Fig. 2 F, G). On the other hand, overexpression of the PEX isoform promoted proliferation and 
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migration of the LuM1 cells (Fig. 7). Therefore, the PEX isoform and domain are responsible 
for MMP-driven cell proliferation, migration and subsequent metastasis of the aggressive 
adenocarcinoma cells.  
MMP3 and MMP9 colocalized with DNA in subcutaneous tumors in vivo (Fig. 6). 
These data indicated potential roles for MMP3 and MMP9 in gene regulation in primary and 
metastatic tumors. We showed that MMP3 localized in cell nuclei in stroma-tumor marginal 
cells in subcutaneous tumors (Fig. 5B, 5C, 6B, 6C), suggesting that MMP3 involves potential 
tumor-stromal interaction such as induction of CAFs, migration, invasion and tumor 
angiogenesis, tumor-immunology interaction through the stroma. In contrast, MMP9 was 
localized in central area of subcutaneous tumors (Fig. 6 B, D). Central area of tumors are often 
necrotic and/or hypoxic where hypoxia-inducible transcription factor (HIF1) controls 
transcription of target genes, including MMP genes [Kondo, 2002] and stem cell genes [Eguchi 
et al., 2018; Keith et al., 2011; Keith and Simon, 2007; Semenza, 2016]. We previously showed that 
MMPs and CTGF/CCN2 were inducible upon hypoxia through distinctive mechanisms [Kondo, 
2002]. MMP9 is one of key proteins induced by HIF1 in tumors whereas CTGF could be 
increased through mRNA stabilization [Kondo, 2002]. Thus, HIF1, MMP9, and CTGF can be 
co-increased at central area of tumors and the induced MMP9 and CTGF can promote tumor 
angiogenesis [Kondo, 2002]. CTGF may be increased by transcriptional role for MMP9 in 
central area of tumors (Fig. 6D), in addition to the role for MMP3 in transcription [Eguchi et al., 
2017; Eguchi et al., 2008] . Indeed, mRNA levels of CTGF were altered in tumors in vivo upon 
knockdown of MMP3 and MMP9 (data not shown). Thus, we are further investigating 
mechanisms underlying MMPs regulation of CTGF and HSPs that may mediate tumor 
progression and metastasis. 
  In addition to the intracellular and non-catalytic roles for MMP3 as shown above, 
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intracellular and non-catalytic MMP9 was suggested in the present study. The approx. 60-kDa 
MMP9 isoforms were significantly detected in the lysate of the metastatic LuM1 cells (Fig. 4G). 
However, any intracellular proteolytic activity of the 60-kDa MMP9 was not detected in the 
lysate of LuM1 cells, even though the gelatinase activities of 90-kDa and 250-kDa MMP9 were 
found (Fig. 4F) and extracellular proteinase activity of 60-kDa MMP9 was detected in the cell 
culture supernatant (Fig. 4H). Thus, the intracellular 60-kDa MMP9 does not possess any 
proteolytic activity or some intracellular factors such as DNA/chromatin might mask the 
proteinase domain.  
 Of note, the non-proteolytic MMPs cannot be directly targeted by metalloproteinase 
inhibitors that block proteolytic pockets. Moreover, the intranuclear MMPs might be difficult to 
be accessed by small molecule drugs, which can be excreted from cancer cells, and are much 
more difficult by molecularly targeted antibody drugs, which are too large to enter into cells and 
nuclei. The siRNA-mediated knockdown tested in the present study significantly and 
sustainably reduced intracellular and extracellular, non-catalytic and catalytic MMPs (Fig. 4, 
S3). These efficient knockdown of various isoforms of MMPs might involve their efficient 
effects to attenuate migration, invasion and metastasis. The RNAi approaches are able to target 
mRNAs that fundamentally encode proteins that are post-translationally modified, processed 
and localized to specific regions. Thus, the RNAi approaches might be more fundamentally 
effective in disease therapies. 
  It was recently reported that MMP3 functions in a coordinated manner with a 
chemokine, IL-8/CXCL8, expressed in melanoma via direct regulation by NFAT1, thus 
promoting tumor progression and metastasis [Shoshan et al., 2016]. Another recent study found 
that interleukin-regulatory transcription factor 8 (IRF-8) directly repressed the Mmp3 gene in 
relatively mild mammary tumor cells, whereas loss of IRF-8 in coordination with gain in Mmp3 
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expression promoted tumor progression and metastasis [Banik et al., 2015.]. These studies were 
done using xenotransplantation of human cancer cells into immunodeficient mice. We consider 
that the present protocol of allogeneic transplantation into an immunologically genetically 
relatively normal host will be useful for further studies of tumor microenvironment and 
immunology.  
 Thus, intracellular and non-proteolytic MMPs have crucial roles in cancer progression. 
The versatile RNAi approach is able to reduce intracellular and extracellular, non-proteolytic 
and proteolytic MMPs at once and thus appears to be significantly effective to attenuate various 
aspects of cancer progression, including proliferation, migration and invasion of cancer cells, 
tumor development and metastasis. 
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FIGURE LEGENDS 
Figure 1. Transcriptome analysis, gene screening, Mmp genes expressed in colon cancer 
cells with different metastatic potential. (A) Flow chart of gene screening. Microarray 
screened 62976 genes. The 479 genes were expressed at more than 10-fold higher level in 
LuM1 as compared to NM11 and Colon26 cells. (B) Venn diagram extracted 104 genes 
involved in invasion, EMT, and metastasis. (C) Heat map analysis of Mmp gene family. The 
gene expression levels relative to the levels in Colon26 were shown. (D) Expression levels of 
Mmp genes in LuM1, NM11 and Colon26 cells. The gene expression level of Mmp3 in LuM1 
was the highest among all Mmp gene family members, as well as compared to that in NM11 and 
Colon26 cells.  
 
Figure 2.  The roles of MMP3 and MMP9 in proliferation, migration, and invasion of the 
metastatic adenocarcinoma cells. (A) Differential in vitro migration activities. Migrated cells per 
well was shown. The migration activity of LuM1 was higher than that of NM11 and Colon26 cells. 
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*p < 0.05 as compared with Colon26 (one way ANOVA). n = 3. (B) Differential in vitro 
invasion activities. *p < 0.05 as compared with Colon26 (one way ANOVA). n = 3. (C) Staining 
of invaded cells. Diff-Quick staining was carried out after invasion assay. Scale bars: 200 µm. 
(D) The mRNA levels of MMP3 in the LuM1 cells transfected with siRNA. Relative mRNA 
levels normalized to Gapdh mRNA levels were shown. *p < 0.05 as compared with control si 
group. ✝p < 0.05 as compared with Mmp9 si group (one way ANOVA). n = 3. (E) The mRNA 
levels of MMP9 in the LuM1 cells transfected with siRNA. Relative mRNA levels normalized 
to Gapdh mRNA levels were shown. *p < 0.05 as compared with control si group. ✝p < 0.05 as 
compared with MMP3 si group (one way ANOVA). n = 3. (F) Growth curves of LuM1 cells 
transfected with MMP-targeting or control siRNA. (G, H) In vitro migration (G) and invasion 
(H) activities altered by MMP3 and/or MMP9 knockdown. Upper panels, quantified migration 
(G) and invasion (H) activities of LuM1 cells transfected with siRNA-targeting MMP3, MMP9, 
MMP3/MMP9 or the control dsRNA. n = 5. *p < 0.05 as compared to the control si group (one 
way ANOVA). Lower panels, migrated (G) and invaded (H) cells stained with Diff-Quick. Scale 
bars: 200 µm. Control si group, n = 5; MMP3 si group, n = 5; MMP9 si group, n = 5; MMP3/9 
si group, n = 6. *p < 0.05 as compared to the control si group. ✝p < 0.05 as compared to the 
MMP9 si group (one way ANOVA). Lower panel, Invaded cells stained with Diff-Quick. Scale 
bars: 200 µm.  
 
Figure 3. Targeting MMP3 and MMP9 attenuated tumor development and metastasis of 
the aggressive colon cancer cells. LuM1 cells transfected with siRNA targeting MMP3 and/or 
MMP9 or non-targeting dsRNA were subcutaneously injected to abdominal walls in mice. The 
primary tumors and the metastatic tumors in lungs were analyzed 20 days post-injection period. 
(A) Representative images of mice bearing subcutaneous primary tumors. (B) Weights of 
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subcutaneous primary tumors. (C) Representative images of lungs with metastatic tumor 
nodules. (D) Numbers of metastatic tumor nodules in lungs. (E) Weights of lungs with 
metastatic tumor nodules. (C-E) Control si group, n = 5; MMP3 si group, n = 5; MMP9 si group, 
n = 5; MMP3/9 si group, n = 6. *p < 0.05, as compared to the control si group (one way 
ANOVA). 
 
Figure 4. Knockdown of non-proteolytic and proteolytic, intracellular and extracellular 
MMP3 and MMP9. (A) Schematic structures of murine MMP3. The structures of protease 
domain-containing 54-kDa MMP3 and non-proteolytic 25-kDa PEX domain of MMP3 are 
shown. The anti-PEX MMP3 antibody EP1186Y recognizes the epitope 450 to 477 position, 
which both the 54-kDa MMP3 and the 25-kDa PEX isoform contain. PG, peptide glycan 
binding domain. PEX, hemopexin-like repeat. Asterisks are positions of nuclear localization 
signals. (B) Schematic structures of approx. 92-95-kDa MMP9 and 64- and 67-kDa MMP9. Fn, 
fibronectin type II domain. PT, PT repeat composed on the tetrapeptide xPTx. (C) Western blot 
showing intracellular isoforms of MMP3 in the LuM1 cells and those knockdown. An arrow 
indicates full-length MMP3 (54-kDa). An arrowhead indicates the intracellular 25-kDa PEX 
isoform of MMP3. WCL, whole cell lysate. (D) Casein zymography of extracellular isoforms of 
MMP3 and those knockdown in the LuM1 cells. An arrow indicates full-length MMP3 
(54-kDa). An arrowhead indicates proteolytic MMP3 monomer or dimer. M, molecular weight 
maker. (E) Intracellular gelatinase activities in the LuM1 cells. The WCLs prepared from LuM1, 
Colon26 and NM11 were examined in zymography. Gelatinase activities at approx. 90-kDa 
(arrow) and 250-kDa (asterisk) were seen. (F) Extracellular gelatinase activities in the culture 
supernatant of the LuM1 cells. Gelatinase activities at approx. 90-kDa (arrow) and 250-kDa 
(asterisk) were seen. (G) Western blotting analysis of intracellular isoforms of MMP9 in the 
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lysate of LuM1 cells and those knockdown. An arrow indicates approx. 90-kDa MMP9. An 
arrowhead indicates intracellular short MMP9 (64- and 67-kDa). An asterisk indicates putative 
intracellular oligomer of MMP9. (H) Gelatin zymography of extracellular MMP9 and those 
knockdown in the LuM1 cells. Gelatinase activities were seen at approx. 90-kDa (arrow, the 
major band), 60-kDa (arrowhead), and 250-kDa (asterisk). M, molecular weight maker. 
 
Figure 5. The subtumoral and subcellular localization of the PEX / MMP3 in primary 
tumors and in metastatic tumors in lungs. LuM1 cells were subcutaneously injected into 
abdominal walls in a mouse. A developed subcutaneous primary tumor (A-C) and a lung lesion 
(D-F) with metastatic tumor nodules were prepared at day 20 after the injection and then 
immunohistochemistry of the PEX / MMP3 was performed. (A) A whole tumor. Scale bar: 500 
µm. (B) A magnified view of the box shown in A. Scale bar: 50 µm. (C) A magnified view of 
the box shown in B. Scale bar: 10 µm. An arrow indicates MMP3 immunostained in a 
cancer-associated fibroblast (CAF)-like cell. Arrowheads indicate nuclear localization of MMP3. 
(D) A whole lung with metastasis. Scale bar: 500 µm. (E) A magnified view of the box shown in 
D. Scale bar: 50 µm. (F) A magnified view of the box shown in E. Scale bar: 10 µm. An arrow 
indicates MMP3 accumulated in the nucleus. An arrowhead indicates MMP3 localization to the 
nuclear margin. 
 
Figure 6. The nuclear PEX / MMP3 found in tumor-stroma marginal area and nuclear 
MMP9 in tumor central area. For immunostaining, an anti-PEX MMP3 antibody and 
anti-MMP9 full-length were used. (A) The scheme of definition of the central area (shown in 
the left photomicrograph), interior, marginal and stromal areas (shown in the right 
photomicrograph) of a tumor. Scale bars, 500 µm (left) and 10 µm (right). The area in the 
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rectangle in the left image was shown with a high power magnification in the right image. (B) 
The positive rate of MMP3 and MMP9 in the nuclei in individual area. n = random 3 fields. *p 
< 0.05 as compared to the nuclear MMP3 positive rate in the stromal area. (C, D) Confocal 
microscopy of subtumoral and subcellular localization of MMP3 (C) and MMP9 (D). Red, 
MMP3 or MMP9. Blue, DNA stained with DAPI. Arrows indicate the MMP3 or MMP9 
localization in the nuclei. Scale bars, 10 µm (C) and 20 µm (D). (E) Confocal microscopy of 
subcellular localization of MMP3/9 in the lung lesion with metastatic cancer cells. Arrows 
indicate MMP3 (left) and MMP9 (right) positive region in the nuclei. Scale bars, 5 µm. 
 
Figure 7. The potent roles of the PEX-domain in proliferation and migration of the 
metastatic cancer cells. (A) Growth curves of the metastatic LuM1 cells transfected with 
pFlag3-PEX-myc or the control vector. *p < 0.05 as compared with control vector. (B) In vitro 
migration activities altered by overexpression of the PEX domain. Upper panels, staining of the 
migrated cells. Scale bars: 200 µm. Lower panel, ratio of migrated cells upon overexpression of 
the PEX domain or the control vector. n = 3. *p < 0.05 as compared with control vector. (C) In 
vitro invasion activities. Upper panels, staining of the invaded cells. Scale bars: 100 µm, Lower 
panel, ratio of the invaded cells upon overexpression of the PEX domain or the control vector. n 
= 3.  
 
SUPPORTING INFORMATION LEGENDS 
Figure S1. Expression signatures of Mmp gene family in rapidly metastatic LuM1, slowly 
metastatic NM11 and the parental Colon26 cells. (A) Differential migration activities of the 
tested cells after the treatment with trypsin or EDTA. LuM1 cells treated with trypsin migrated 
more than other cell lines or EDTA-treated LuM1 cells. EDTA is a chelator for metal. MMPs 
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coordinate a zinc ion at their activity pockets. EDTA chelates zinc ions coordinated in proteins, 
including MMPs. The chelation of zinc ion in MMPs may alter their structures and functions. 
Trypsin cleaves and alters cell surface proteins, possibly including receptor-bound MMPs and 
MT-MMPs. Scale bars: 200 µm. (B) Quality check of the total RNA by agarose gel 
electrophoresis. The quality of RNA samples were confirmed before microarray and RT-qPCR 
analysis. (C) Heat map showing relative expression levels of all Mmp gene family members. 
The gene expression level of Mmp3 in LuM1 was the highest among all Mmp gene family 
members, as well as compared to that in NM11 and Colon26 cells.  
 
Figure S2. Targeted knockdown of MMP3 and/or MMP9. (A) A flowchart of knockdown 
studies. Cells were cultured for 48 hours after transfection of siRNA. We then performed 
RT-qPCR (Fig. 2D, E), Western blotting analysis (Fig. 4C, G), migration assay (Fig. 2G), 
invasion assay (Fig. 2H), and subcutaneous injection (Fig. 3). Cells transfected with siRNA 
were cultured for 48, 72 or 96 hours for zymography while the media were replaced to 
serum-free media 24 hours prior to harvest of culture supernatant. To analyze mRNA levels in 
tumors in vivo, total RNA was extracted from subcutaneous tumors on the day 10 after 
subcutaneous injection. Lung metastasis assay and IHC were performed on the day 20 after 
subcutaneous injection. (B) Representative photomicrographs of LuM1 cells transfected with 
siRNAs. Scale bars: 100 µm. (C) Gelatin zymography to examine sustainability of RNAi effect. 
LuM1 cells were transfected with siRNA targeting Mmp9 or non-silencing control dsRNA. Cell 
culture supernatants (5 ml) were collected at 48, 72, and 96 hours after transfection, then 
concentrated to a 1/20 volume. Protein samples (13.2 µg) were subjected to SDS-PAGE for 
gelatin zymography (upper panel). The #1 and #2 indicate biological duplicates. The intensities 
of the bands were quantified by using ImageJ and shown in the graph (lower panel). (D) In vivo 
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gene expression levels of Mmp3 in the MMP3-knockdown tumor (upper) and the levels of 
Mmp9 in the MMP9-knockdown tumor (lower). Total RNA was prepared from the tumor on the 
day 10 after the subcutaneous injection of siRNA-transfected LuM1 cells and qRT-PCR was 
performed. Relative mRNA levels normalized to Actb mRNA levels were shown. 
Figure S3. Full images of Western blot and zymography shown in Fig 6. (A) Western 
blotting analysis of intracellular isoforms of MMP3 in the LuM1 cells and those knockdown. 
(B) Casein zymography of extracellular isoforms of MMP3 and those knockdown in the LuM1 
cells. (C) Intracellular gelatinase activities in the LuM1 cells. (D) Extracellular gelatinase 
activities in the culture supernatant of the LuM1 cells. (E) Western blotting analysis of 
intracellular isoforms of MMP9 in the lysate of LuM1 cells and those knockdown. (F) Gelatin 
zymography of extracellular MMP9 and those knockdown in the LuM1 cells. 
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Table 1. Functional annotation clustering.  
Annotation Cluster 1   Enrichment Score: 2.49 P-value 
GO:0044421   extracellular region part 0.0010483 
GO:0005576   extracellular region 
 
0.0050501 
GO:0005615   extracellular space 
 
0.0064459 
Annotation Cluster 2   Enrichment Score: 2.11 P-value 
GO:0007155   cell adhesion 
 
0.0046972 
GO:0022610   biological adhesion 
 
0.0047962 
GO:0016337   cell-cell adhesion 
 
0.0213548 
Annotation Cluster 3   Enrichment Score: 1.90 P-value 
GO:0006954   inflammatory response 0.00592 
GO:0006952   defense response 
 
0.0092881 
GO:0009611   response to wounding 
 
0.0107201 
GO:0002252   immune effector process 0.0416591 
 Annotation Cluster 4   Enrichment Score: 1.83 P-value 
GO:0030246   carbohydrate binding 
 
4.37E-04 
GO:0030247   polysaccharide binding 0.0119368 
GO:0001871   pattern binding 
 
0.0119368 
GO:0005539   glycosaminoglycan binding 0.0228992 
GO:0008201   heparin binding   0.0477234 
Genes expressed at a 10-fold greater level in LuM1 as compared to those in NM11 and Colon26 
cells were analyzed. 
 
Table 2. Ranking of altered pathways in LuM1 as compared to NM11 and Colon26 cells. 
Page 32 of 79
John Wiley & Sons, Inc.
Journal of Cellular Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Category Term P-value 
KEGG_PATHWAY  mmu04060:Cytokine-cytokine receptor interaction 0.0202 
KEGG_PATHWAY  mmu04062:Chemokine signaling pathway 0.0253 
KEGG_PATHWAY  mmu04142:Lysosome 0.0283 
KEGG_PATHWAY  mmu04020:Calcium signaling pathway 0.0325 
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